The emergence of methicillin-resistant Staphylococcus aureus (MRSA) and its robust biofilm-forming capability pose severe threats to public health, livestock production, and food safety, and underscores the urgent need for novel antibacterial and anti-biofilm agents. In this study, we identified and characterized a novel bacteriocin, PFB252, derived from Bacillus velezensis through a multistep purification process involving acid precipitation, TA-GF75 gel column chromatography, Tiderose Q HP anion-exchange chromatography (TRUKING, Changsha, China), and reversed-phase HPLC. PFB252 exhibited remarkable thermal stability, pH tolerance, and resistance to enzymatic degradation, and demonstrated potent antibacterial activity against MRSA. At subinhibitory concentrations (1/32× minimum inhibitory concentration [MIC] and 1/16× MIC), PFB252 significantly disrupted biofilm formation and impaired the metabolic viability of embedded bacteria, and it drastically reduced extracellular polysaccharide, the key component of the biofilm matrix. Transcriptional analysis further revealed that PFB252 at subinhibitory concentrations downregulated critical biofilm-associated genes. PFB252 exhibited strong antimicrobial efficacy in dairy applications and could reduce MRSA counts in milk from 103 to <10 cfu/mL within 4 d at MIC and maintain suppression in cheese below 102 cfu/g over 7 d. These properties highlight PFB252's potential as a natural biopreservative for combating MRSA in food systems and offer a promising solution for food safety applications.
1 January 2020 in Bioorganic & Medicinal Chemistry Letters
The Colony-Stimulating Factor 1 (CSF-1) and its receptor (CSF1R) constitute an important axis that regulates the phenotype of most tissue-resident macrophages. Endogenous cytokine ligation and oncogenic mutations of CSF1R trigger the activation of several downstream pro-survival kinase cascades, thereby enhancing tumor cell proliferation and disease progression. Tumor-associate macrophages (TAMs) harboring activated CSF1R release tumorigenic cytokines, thus further deconditioning tumor immune microenvironment to a pro-tumoral phenotype. With the recent success of pexidartinib for the treatment of tenosynovial giant cell tumor, CSF1R pathway blockage has emerged as a promising TAM-targeting approach in certain types of cancers. More interventions to CSF1R, including monotherapy and combinatorial therapy, have advanced to clinical trials for a broader spectrum of cancers, highlighting such strategy to benefit cancer immunotherapy.